More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Method to Sensitize Tumors to Chemotherapy by Inhibiting PSMA

SK2013-083

SUMMARY OF INVENTION

Prostate-specific membrane antigen (PSMA) is a transmembrane glutamate carboxypeptidase that is found in prostate cancers and the neovasculature of most solid tumors, however, it is absent from healthy prostate glands and normal vessels. PSMA, through its role in a complex signaling cascade, promotes prostate cancer progression, as well as vessel formation in tumors (known as neoangiogenesis).

MSK investigators have determined that modulating PSMA levels and enzymatic activity can lead to alterations in cancer cell metabolism and proliferation, as well as tumor oxygenation, through changes in the tumor’s vascular bed. Treating tumors with PSMA inhibitors has been shown both in cells and in vivo to inhibit tumor growth and also to enhance the efficacy of chemotherapeutic drugs (anti-androgens), potentially improving treatment outcomes for prostate cancer patients. Using new PET tracers, PSMA imaging can be used to interrogate these critical signaling pathways in prostate cancer to obtain information on prognosis and therapy success.

ADVANTAGES

  • This method inhibits both tumor progression and vascularization.

  • The intended target PSMA has high correlation with prostate cancer; however there is also potential for future application as a method of use targeting tumor vasculature in anti-angiogenic therapy for other cancers mediated by PSMA.

MARKET OPPORTUNITIES

The potential market is large, since prostate cancer is one of the most frequently diagnosed cancers in men, and is the most common cause of cancer-related death after lung cancer. Currently, the incidence rate of prostate cancer in the U.S. is approaching one in six men.

STAGE OF DEVELOPMENT

Preclinical

PATENT INFORMATION

National phase applications filed in the U.S., Canada, EU, Australia, Japan, and China on April 10, 2017

LEAD INVESTIGATOR

Jan Grimm, PhD, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, MSK

CONTACT INFORMATION

Eileen Flowers, PhD

Licensing Manager
Tel: 646-888-1067
E-mail:
flowerse@mskcc.org

Stage of Development

In vitro

Indications

Types